To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Serum nuclear magnetic re… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.

Journal article
Authors Martin Stenson
Anders Pedersen
Sverker Hasselblom
Herman Nilsson-Ehle
B Göran Karlsson
Rui Pinto
Per-Ola Andersson
Published in Leukemia & lymphoma
Volume 57
Issue 8
Pages 1814-1822
ISSN 1029-2403
Publication year 2016
Published at Swedish NMR Centre at Göteborg University
Institute of Medicine
Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
Pages 1814-1822
Language en
Subject categories Biological Sciences, Hematology


The prognosis for diffuse large B-cell lymphoma (DLBCL) patients with early relapse or refractory disease is dismal. To determine if clinical outcome correlated to diverse serum metabolomic profiles, we used (1)H nuclear magnetic resonance (NMR) spectroscopy and compared two groups of DLBCL patients treated with immunochemotherapy: i) refractory/early relapse (REF/REL; n=27) and ii) long-term progression-free (CURED; n = 60). A supervised multivariate analysis showed a separation between the groups. Among discriminating metabolites higher in the REF/REL group were the amino acids lysine and arginine, the degradation product cadaverine and a compound in oxidative stress (2-hydroxybutyrate). In contrast, the amino acids aspartate, valine and ornithine, and a metabolite in the glutathione cycle, pyroglutamate, were higher in CURED patients. Together, our data indicate that NMR-based serum metabolomics can identify a signature for DLBCL patients with high-risk of failing immunochemotherapy, prompting for larger validating studies which could lead to more individualized treatment of this disease.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?